Macquarie: Raises JD HEALTH target price to HKD 74.57, maintains "Outperform" rating
I'm PortAI, I can summarize articles.
Macquarie raised the target price for JD HEALTH by 20% to HKD 74.57, maintaining an "Outperform" rating. It is expected that revenue will grow by 22% year-on-year in the third quarter of 2025, and the adjusted net profit margin in the second half of the year will reach 8.1%, an increase of 90 basis points year-on-year. Macquarie believes that the company's position in the main healthcare product distribution channels will continue to strengthen, benefiting from the launch of new drugs and increased advertising spending, with an overall gross profit margin expected to expand by 1.5 percentage points year-on-year to 23.7%
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments